Small peptide-modified nanostructured lipid carriers distribution and targeting to EGFR-overexpressing tumor in vivo. (June 2014)

• Record Type: Journal Article
• Authors: Han, Cuiyan; Li, Yao; Sun, Mingshuang; Liu, Chang; Ma, Xiaoxing; Yang, Xinggang; Yuan, Yue; Pan, Weisan
• Is Part Of: Artificial cells, nanomedicine, and biotechnology. Volume 42:Number 3(2014:Jun.)
• Page Start: 161
• Page End: 166
• Publication Date: 2014-06
• Subjects: Artificial cells -- Periodicals; Nanotechnology -- Periodicals; Blood substitutes -- Periodicals; Tissue engineering -- Periodicals; Molecules -- Periodicals; Biotechnology -- Periodicals; 615.39
• DOI: 10.3109/21691401.2013.801848
• Languages: English
• ISSNs: 2169-1401

Abstract

<abstract> <title>Abstract</title> <p>Ala-Glu-Tyr-Leu-Arg (AEYLR) was identified as a small peptide ligand targeting epidermal growth factor receptors (EGFR) <italic>in vitro</italic> in our previous study. The <italic>in vivo</italic> targeting ability of AEYLR and AEYLR-conjugated nanostructured lipid carriers (NLC) was studied in this paper. Near-infrared fluorescent (NIFR) dye 1, 1'-dioctadecyltetramethyl indotricarbocyanine iodide (DiR)-loaded and AEYLR-modified NLC (A-D-NLC) were prepared. The average diameter, zeta potential, coupling efficiency between AEYLR and NLC and the amount of DiR released from A-D-NLC were used to evaluate their <italic>in vivo</italic> characteristics. AEYLR was labeled by Cy7 and A549 xenograft tumor-bearing mice model were establish. The <italic>in vivo</italic> distribution in tumor-bearing mice of A-D-NLC and Cy7-AEYLR was examined using NIRF imaging experiments at different times post-injection. AEYLR and AEYLR-conjugated NLC showed obvious targeting to A549 xenograft tumor compared with the control group. These results suggested that AEYLR-modified NLC could be considered as a promising targeted delivery system for combination cancer chemotherapy to improve therapeutic efficacy and to minimize adverse effects.</p> </abstract>